1) Hirose T, Kikuchi T:Aripiprazole, a novel antipsychotic agent:Dopamine D2 receptor partial agonist. J Med Invest 52:284-290, 2005
2) Hori H, Yoshimura R, Katsuki A, et al:Several prescription patterns of antipsychotic drugs influence cognitive functions in Japanese chronic schizophrenia patients. Int J Psychiatry Clin Pract 16:138-142, 2012
3) Iyo M, Tadokoro S, Kanahara N, et al:Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis. J Clin Psychopharmacol 33:398-404, 2013
4) Kimura H, Kanahara N, Watanabe H, et al:Potential treatment strategy of risperidone in long-acting injectable form for schizophrenia with dopamine supersensitivity psychosis. Schizophr Res 145:130-131, 2013
5) 村崎光邦,西川弘之,石橋正:ドパミン-セロトニン拮抗薬—新規統合失調症治療薬blonanserinの受容体結合特性.臨床精神薬理 11:845-854, 2008
6) 助川鶴平:抗精神病薬の減量単純化のための減量速度一覧表の作成.臨床精神薬理 14:511-515, 2011
7) 助川鶴平:抗精神病薬使用の適正化について—減量単純化の試み.日本臨牀 71:712-717, 2013
8) Sukegawa T, Inagaki A, Yamanouchi Y, et al:Study protocol:Safety correction of high dose antipsychotic polypharmacy in Japan. BMC Psychiatry 14:103, 2014
9) 助川鶴平,山之内芳雄,稲垣中:抗精神病薬使用の適正化について.臨床精神薬理17:1353-1359, 2014
10) Tadokoro S, Okamura N, Sekine Y, et al:Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis. Schizophr Bull 38:1012-1020, 2012
11) Takase M, Kanahara N, Oda Y, et al:Dopamine supersensitivity psychosis and dopamine partial agonist:A retrospective survey of failure of switching to aripiprazole in schizophrenia. J Psychopharmacol 29:383-389, 2015
12) 渡邉博幸:統合失調症薬物療法の適正化に関する3つの提言.臨床精神薬理 17:1343-1352, 2014
13) 吉尾隆:抗精神病薬の多剤併用大量処方の実態—精神科臨床薬学研究会(PCP研究会)処方実態調査から.精神経誌 114:690-695, 2012